Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Gerontology ; 62(3): 371-80, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26330171

RESUMO

Parkinson's disease (PD) affects an estimated 7-10 million people worldwide and remains without definitive or disease-modifying treatment. There have been many recent developments in cell-based therapy (CBT) to replace lost circuitry and provide chronic biological sources of therapeutic agents to the PD-affected brain. Early neural transplantation studies underscored the challenges of immune compatibility, graft integration and the need for renewable, autologous graft sources. Neurotrophic factors (NTFs) offer a potential class of cytoprotective pharmacotherapeutics that may complement dopamine (DA) replacement and CBT strategies in PD. Chronic NTF delivery may be an integral goal of CBT, with grafts consisting of autologous drug-producing (e.g., DA, NTF) cells that are capable of integration and function in the host brain. In this mini-review, we outline the past experience and recent advances in NTF technology and CBT as promising and integrated approaches for the treatment of PD.


Assuntos
Terapia Baseada em Transplante de Células e Tecidos/métodos , Células-Tronco Pluripotentes Induzidas/transplante , Fatores de Crescimento Neural/uso terapêutico , Doença de Parkinson/terapia , Encéfalo/metabolismo , Dopamina/metabolismo , Transplante de Tecido Fetal/métodos , Vetores Genéticos , Fator Neurotrófico Derivado de Linhagem de Célula Glial/uso terapêutico , Humanos , Mesencéfalo/transplante , Neurturina/uso terapêutico , Doença de Parkinson/metabolismo
2.
Neurobiol Aging ; 34(1): 35-61, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22926166

RESUMO

Neurotrophic factors have long shown promise as potential therapies for age-related neurodegenerative diseases. However, 20 years of largely disappointing clinical results have underscored the difficulties involved with safely and effectively delivering these proteins to targeted sites within the central nervous system. Recent progress establishes that gene transfer can now likely overcome the delivery issues plaguing the translation of neurotrophic factors. This may be best exemplified by adeno-associated virus serotype-2-neurturin (CERE-120), a viral-vector construct designed to deliver the neurotrophic factor, neurturin to degenerating nigrostriatal neurons in Parkinson's disease. Eighty Parkinson's subjects have been dosed with CERE-120 (some 7+ years ago), with long-term, targeted neurturin expression confirmed and no serious safety issues identified. A double-blind, controlled Phase 2a trial established clinical "proof-of-concept" via 19 of the 24 prescribed efficacy end points favoring CERE-120 at the 12-month protocol-prescribed time point and all but one favoring CERE-120 at the 18-month secondary time point (p = 0.007 and 0.001, respectively). Moreover, clinically meaningful benefit was seen with CERE-120 on several specific protocol-prescribed, pairwise, blinded, motor, and quality-of-life end points at 12 months, and an even greater number of end points at 18 months. Because the trial failed to meet the primary end point (Unified Parkinson's Disease Rating Scale motor-off, measured at 12 months), a revised multicenter Phase 1/2b protocol was designed to enhance the neurotrophic effects of CERE-120, using insight gained from the Phase 2a trial. This review summarizes the development of CERE-120 from its inception through establishing "clinical proof-of-concept" and beyond. The translational obstacles and issues confronted, and the strategies applied, are reviewed. This information should be informative to investigators interested in translational research and development for age-related and other neurodegenerative diseases.


Assuntos
Envelhecimento , Terapia Genética , Doenças Neurodegenerativas/terapia , Neurturina/uso terapêutico , Doença de Parkinson/terapia , Animais , Vetores Genéticos/fisiologia , Humanos , Neurturina/biossíntese , Neurturina/genética
3.
Curr Mol Med ; 12(10): 1311-8, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22834832

RESUMO

Parkinson's disease (PD) is an age-related and the second most common neurodegenerative disorder beyond Alzheimer's disease. A neuropathological hallmark of PD is a prominent loss of dopaminergic neurons in the substantia nigra projecting into the caudate and putamen. Oral administration of L-dopa and/or dopamine agonists ameliorates cardinal motor symptoms of PD. However, an intermittent and long-term treatment with L-dopa frequently induces adverse side effects such as motor fluctuations and dyskinesia. As alternative therapeutic strategies, the following four approaches are currently under evaluation for clinical gene therapy trials in PD; 1) recombinant adeno-associated virus 2 system encoding aromatic L-amino acid decarboxylase (AADC), 2) glutamic acid decarboxylase (GAD) and 3) Neurturin, and 4) equine infectious anemia virus-based lentiviral system encoding AADC, tyrosine hydroxylase (TH) and GTP cyclohydrolase I (GCH) in a single transcriptional unit. GAD and Neurturin have been assessed in double blind placebocontrolled phase II studies; GAD showed a significant improvement in motor function, and Neurturin, although it failed to show significant effects at 12 months post-treatment, exhibited promising outcomes in additional examinations at 18 months. The other two approaches also represented significant effects in phase I or I/II studies. Adverse side effects due to surgery have not been observed. Here, we review preclinical and clinical trials encouraging further investigations of curative treatment for the patients suffering from PD.


Assuntos
Terapia Genética , Doença de Parkinson/terapia , Descarboxilases de Aminoácido-L-Aromático/genética , Descarboxilases de Aminoácido-L-Aromático/uso terapêutico , Dependovirus/genética , Agonistas de Dopamina/uso terapêutico , Neurônios Dopaminérgicos/patologia , GTP Cicloidrolase/genética , GTP Cicloidrolase/uso terapêutico , Técnicas de Transferência de Genes , Vetores Genéticos , Glutamato Descarboxilase/genética , Glutamato Descarboxilase/uso terapêutico , Humanos , Vírus da Anemia Infecciosa Equina/genética , Levodopa/uso terapêutico , Neurturina/uso terapêutico , Doença de Parkinson/genética , Tirosina 3-Mono-Oxigenase/genética , Tirosina 3-Mono-Oxigenase/uso terapêutico
5.
Mov Disord ; 26(1): 27-36, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21322017

RESUMO

BACKGROUND: AAV2-neurturin (CERE-120) is designed to deliver the neurotrophic-factor, neurturin, to the striatum to restore and protect degenerating nigrostriatal neurons in Parkinson's disease (PD). A common hypothesis is that following expression in the striatum, neurotrophic-factors like neurturin (NRTN) will be transported from degenerating terminals to their cell bodies in the substantia nigra pars compacta (SNc). METHODS: We tested this concept using immunohistochemistry, comparing the bioactivity of AAV2-neurturin in brains of PD patients versus those of nonhuman primates similarly treated. RESULTS: NRTN-immunostaining in the targeted striatum was seen in all PD cases (mean putaminal coverage: ∼15% by volume); comparable expression was observed in young, aged, and parkinsonian monkeys. In the SNc cell bodies, however, only rare evidence of neurturin was seen in PD, while ample evidence of intense nigral-NRTN was observed in all monkeys. NRTN-expression was associated with occasional, sparse TH-induction in the striatum of PD, but nothing apparent in the SNc. In primates, NRTN produced robust TH-induction throughout the nigrostriatal neurons. DISCUSSION: These data provide the first evidence that gene therapy can increase expression of a neurotrophic-factor deep in the PD brain and that clear but modest enhancement of degenerating neurons can be induced. They also provide important insight regarding deficiencies in the status of nigrostriatal neurons in advanced PD, suggesting that serious axon-transport deficits reduced the bioactivity of AAV2-NRTN by limiting the protein exposed to the cell body. Thus, future efforts using neurotrophic-factors to treat neurodegenerative diseases will need to target both the terminal fields and the cell bodies of degenerating neurons to assure maximal benefit is achieved.


Assuntos
Corpo Estriado/metabolismo , Terapia Genética/métodos , Intoxicação por MPTP/terapia , Neurturina/uso terapêutico , Doença de Parkinson/terapia , Idoso , Animais , Dependovirus/genética , Dependovirus/metabolismo , Modelos Animais de Doenças , Lateralidade Funcional , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Intoxicação por MPTP/induzido quimicamente , Intoxicação por MPTP/metabolismo , Intoxicação por MPTP/patologia , Macaca mulatta , Masculino , Pessoa de Meia-Idade , Neurturina/genética , Neurturina/metabolismo , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Tirosina 3-Mono-Oxigenase/metabolismo
7.
Lancet Neurol ; 9(12): 1164-1172, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20970382

RESUMO

BACKGROUND: In an open-label phase 1 trial, gene delivery of the trophic factor neurturin via an adeno-associated type-2 vector (AAV2) was well tolerated and seemed to improve motor function in patients with advanced Parkinson's disease. We aimed to assess the safety and efficacy of AAV2-neurturin in a double-blind, phase 2 randomised trial. METHODS: We did a multicentre, double-blind, sham-surgery controlled trial in patients with advanced Parkinson's disease. Patients were randomly assigned (2:1) by a central, computer generated, randomisation code to receive either AAV2-neurturin (5·4 × 10¹¹ vector genomes) injected bilaterally into the putamen or sham surgery. All patients and study personnel with the exception of the neurosurgical team were masked to treatment assignment. The primary endpoint was change from baseline to 12 months in the motor subscore of the unified Parkinson's disease rating scale in the practically-defined off state. All randomly assigned patients who had at least one assessment after baseline were included in the primary analyses. This trial is registered at ClinicalTrials.gov, NCT00400634. RESULTS: Between December, 2006, and November, 2008, 58 patients from nine sites in the USA participated in the trial. There was no significant difference in the primary endpoint in patients treated with AAV2-neurturin compared with control individuals (difference -0·31 [SE 2·63], 95% CI -5·58 to 4·97; p=0·91). Serious adverse events occurred in 13 of 38 patients treated with AAV2-neurturin and four of 20 control individuals. Three patients in the AAV2-neurturin group and two in the sham surgery group developed tumours. INTERPRETATION: Intraputaminal AAV2-neurturin is not superior to sham surgery when assessed using the UPDRS motor score at 12 months. However, the possibility of a benefit with additional targeting of the substantia nigra and longer term follow-up should be investigated in further studies. FUNDING: Ceregene and Michael J Fox Foundation for Parkinson's Research.


Assuntos
Dependovirus/fisiologia , Terapia Genética/métodos , Neurturina/genética , Neurturina/uso terapêutico , Doença de Parkinson/terapia , Adulto , Idoso , Análise de Variância , Dependovirus/genética , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Atividade Motora/fisiologia , Neurturina/metabolismo , Doença de Parkinson/genética , Doença de Parkinson/fisiopatologia , Putamen/metabolismo , Putamen/fisiologia , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
9.
Lancet Neurol ; 7(5): 400-8, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18387850

RESUMO

BACKGROUND: There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin. METHODS: In this phase I, open-label clinical trial, 12 patients aged 35-75 years with a diagnosis of PD for at least 5 years in accordance with the UK Brain Bank Criteria received bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120). The first six patients received doses of 1.3x10(11) vector genomes (vg)/patient, and the next six patients received 5.4x10(11) vg/patient. This trial is registered with ClinicalTrials.gov, number NCT00252850. FINDINGS: The procedure was well tolerated. Extensive safety monitoring in all patients revealed no clinically significant adverse events at 1 year. Several secondary measures of motor function showed improvement at 1 year; for example, a mean improvement in the off-medication motor subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) of 14 points (SD 8; p=0.000121 [36% mean increase; p=0.000123]) and a mean increase of 2.3 h (2; 25% group mean increase; p=0.0250) in on time without troublesome dyskinesia were seen. Improvements in several secondary measures were not significant, including the timed walking test in the off condition (p=0.053), the Purdue pegboard test of hand dexterity (p=0.318), the reduction in off time (p=0.105), and the activities of daily living subscore (part II) of the UPDRS (p=0.080). (18)F-levodopa-uptake PET did not change after treatment with either dose of CERE-120. INTERPRETATION: The initial data support the safety, tolerability, and potential efficacy of CERE-120 as a possible treatment for PD; however, these results must be viewed as preliminary until data from blinded, controlled clinical trials are available. FUNDING: Ceregene; Michael J Fox Foundation for Parkinson's Research.


Assuntos
Dependovirus/fisiologia , Terapia Genética/métodos , Neurturina/uso terapêutico , Doença de Parkinson/terapia , Putamen/efeitos dos fármacos , Adulto , Idoso , Relação Dose-Resposta a Droga , Sistemas de Liberação de Medicamentos , Feminino , Vetores Genéticos/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Neurturina/biossíntese , Neurturina/genética , Doença de Parkinson/patologia , Doença de Parkinson/fisiopatologia
11.
Mov Disord ; 22(8): 1124-32, 2007 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-17443702

RESUMO

Neurturin (NTN) is a potent survival factor for midbrain dopaminergic neurons. CERE-120, an adeno-associated virus type 2 (AAV2) vector encoding human NTN (AAV2-NTN), is currently being developed as a potential therapy for Parkinson's disease. This study examined the bioactivity and safety/tolerability of AAV2-NTN in the aged monkey model of nigrostriatal dopamine insufficiency. Aged rhesus monkeys received unilateral injections of AAV2-NTN into the caudate and putamen, with each animal therefore serving as its own control. Robust expression of NTN within the nigrostriatal system was observed 8 months postadministration. (18)F-fluorodopa imaging using positron emission tomography revealed statistically significant increases in (18)F-fluorodopa uptake in the injected striatum compared with the uninjected side at 4 and 8 months. In addition, at 8 months postadministration, a significant enhancement in tyrosine hydroxylase immunoreactive fibers and an increase in the number of tyrosine hydroxylase immunoreactive cells was observed in the AAV2-NTN injected striatum compared with the uninjected side. Robust activation of phosphorylated extracellular signal-regulated kinase immunoreactivity in the substantia nigra was also observed. Histopathological analyses revealed no adverse effects of AAV2-NTN in the brain. Collectively, these results are consistent with the neurotrophic effects of NTN on the dopaminergic nigrostriatal system and extend the growing body of evidence supporting the concept that AAV2-NTN may have therapeutic benefit for Parkinson's disease.


Assuntos
Envelhecimento/fisiologia , Corpo Estriado , Dependovirus/metabolismo , Modelos Animais de Doenças , Dopamina/metabolismo , Neurturina/uso terapêutico , Doença de Parkinson , Substância Negra , Animais , Corpo Estriado/metabolismo , Corpo Estriado/patologia , Corpo Estriado/virologia , Feminino , Fluordesoxiglucose F18/farmacocinética , Macaca mulatta , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Doença de Parkinson/virologia , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/farmacocinética , Substância Negra/metabolismo , Substância Negra/patologia , Substância Negra/virologia
12.
Neurobiol Dis ; 26(2): 375-84, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17336076

RESUMO

Huntington's disease (HD) is a devastating neurodegenerative disease characterized by the selective loss of neurons in the striatum and cerebral cortex. This study tested the hypothesis that an adenoassociated viral (AAV2) vector encoding for the trophic factor neurturin (NTN) could provide neuroprotection in the rat 3-nitropropionic acid (3NP) model of HD. Rats received AAV2-NTN (CERE-120), AAV2-eGFP or Vehicle, followed 4 weeks later by the mitochondrial toxin 3NP. 3NP induced motor impairments were observed on the rotarod test, the platform test, and a clinical rating scale in all groups. However, each of these deficits was attenuated by AAV2-NTN (CERE-120). Stereological counts revealed a significant protection of NeuN-ir striatal neurons from 3NP toxicity by AAV2-NTN. These data support the concept that AAV2-NTN might be a valuable treatment for patients with Huntington's disease.


Assuntos
Corpo Estriado/metabolismo , Terapia Genética/métodos , Doença de Huntington/terapia , Degeneração Neural/terapia , Neurônios/metabolismo , Neurturina/genética , Animais , Contagem de Células , Morte Celular/genética , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/fisiopatologia , Citoproteção/genética , Proteínas de Ligação a DNA , Dependovirus/genética , Modelos Animais de Doenças , Técnicas de Transferência de Genes/tendências , Vetores Genéticos/genética , Doença de Huntington/induzido quimicamente , Doença de Huntington/genética , Masculino , Atividade Motora/genética , Degeneração Neural/fisiopatologia , Degeneração Neural/prevenção & controle , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/patologia , Neurotoxinas , Neurturina/uso terapêutico , Nitrocompostos , Proteínas Nucleares/metabolismo , Propionatos , Ratos , Ratos Endogâmicos Lew , Recuperação de Função Fisiológica/genética , Resultado do Tratamento
13.
Parkinsonism Relat Disord ; 13(2): 77-88, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16963309

RESUMO

Genetically engineered neural stem cell (NSC) lines are promising vectors for the treatment of regenerative diseases, especially Parkinson's disease (PD). Neurturin (NTN), a member of the glial cell line-derived neurotrophic factor-family, has been demonstrated to act specifically on mesencephalic dopaminergic neurons, suggesting its therapeutic potential for PD. Here, we have generated a NTN-secreting c17.2 NSC line and investigated the protective effect of NTN-c17.2 on PD rat models. These NTN-releasing NSCs engrafted and integrated in the host striatum with good success, gave rise to neurons, astrocytes and oligodendrocytes, and maintained stable, high-level NTN expression. In addition, inverse transfer of NTN protein into the substantia nigra (SN) was able to protect dopaminergic neurons from 6-OHDA toxicity. Observation of rotational behavior showed that the NTN group performed significantly better than the Mock group, and the protective effect of NTN lasted for at least 4 months. HPLC tests indicated that the contents of neurotransmitters (e.g. dopamine) in the corpus striatum area of the NTN-c17.2 group and the Mock-c17.2 group were significantly higher than in the PBS group, but there was no significant difference between expression in the NTN-c17.2 and Mock-c17.2 groups. Taken together, our results suggest that transplantation of NTN-secreting NSCs exerted protective on PD rat models.


Assuntos
Dopamina/metabolismo , Fármacos Neuroprotetores/uso terapêutico , Neurturina/uso terapêutico , Doença de Parkinson/patologia , Doença de Parkinson/prevenção & controle , Células-Tronco/fisiologia , Adrenérgicos/toxicidade , Animais , Apomorfina/farmacologia , Comportamento Animal , Contagem de Células , Linhagem Celular , Modelos Animais de Doenças , Masculino , Atividade Motora/efeitos dos fármacos , Proteínas do Tecido Nervoso/metabolismo , Neurturina/biossíntese , Oxidopamina/toxicidade , Doença de Parkinson/etiologia , Doença de Parkinson/fisiopatologia , Ratos , Ratos Sprague-Dawley , Transplante de Células-Tronco/métodos , Tirosina 3-Mono-Oxigenase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...